BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38532630)

  • 41. Towards safe therapy for immunodeficiency.
    Tsai SQ
    Nat Biomed Eng; 2017 Dec; 1(12):937-938. PubMed ID: 31015711
    [No Abstract]   [Full Text] [Related]  

  • 42. Genome editing in human hematopoietic stem and progenitor cells via CRISPR-Cas9-mediated homology-independent targeted integration.
    Bloomer H; Smith RH; Hakami W; Larochelle A
    Mol Ther; 2021 Apr; 29(4):1611-1624. PubMed ID: 33309880
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ex vivo culture resting time impacts transplantation outcomes of genome-edited human hematopoietic stem and progenitor cells in xenograft mouse models.
    Demirci S; Khan MBN; Hinojosa G; Le A; Leonard A; Essawi K; Gudmundsdottir B; Liu X; Zeng J; Inam Z; Chu R; Uchida N; Araki D; London E; Butt H; Maitland SA; Bauer DE; Wolfe SA; Larochelle A; Tisdale JF
    Cytotherapy; 2024 Jun; 26(6):641-648. PubMed ID: 38506770
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The CCR5 Gene Edited CD34
    Karuppusamy KV; Demosthenes JP; Venkatesan V; Christopher AC; Babu P; Azhagiri MK; Jacob A; Ramalingam VV; Rangaraj S; Murugesan MK; Marepally SK; Varghese GM; Srivastava A; Kannangai R; Thangavel S
    Front Immunol; 2022; 13():792684. PubMed ID: 35359982
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preclinical evaluation for engraftment of CD34
    Uchida N; Li L; Nassehi T; Drysdale CM; Yapundich M; Gamer J; Haro-Mora JJ; Demirci S; Leonard A; Bonifacino AC; Krouse AE; Linde NS; Allen C; Peshwa MV; De Ravin SS; Donahue RE; Malech HL; Tisdale JF
    Cell Rep Med; 2021 Apr; 2(4):100247. PubMed ID: 33948577
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Case Report: A Novel IL2RG Frame-Restoring Rescue Mutation Mimics Early T Cell Engraftment Following Haploidentical Hematopoietic Stem Cell Transplantation in a Patient With X-SCID.
    Steininger J; Leiss-Piller A; Geier CB; Rossmanith R; Elfeky R; Bra D; Pichler H; Lawitschka A; Zubarovskaya N; Artacker G; Matthes-Leodolter S; Eibl MM; Wolf HM
    Front Immunol; 2021; 12():644687. PubMed ID: 33959125
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Highly efficient therapeutic gene editing of human hematopoietic stem cells.
    Wu Y; Zeng J; Roscoe BP; Liu P; Yao Q; Lazzarotto CR; Clement K; Cole MA; Luk K; Baricordi C; Shen AH; Ren C; Esrick EB; Manis JP; Dorfman DM; Williams DA; Biffi A; Brugnara C; Biasco L; Brendel C; Pinello L; Tsai SQ; Wolfe SA; Bauer DE
    Nat Med; 2019 May; 25(5):776-783. PubMed ID: 30911135
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lentivirus Mediated Correction of Artemis-Deficient Severe Combined Immunodeficiency.
    Punwani D; Kawahara M; Yu J; Sanford U; Roy S; Patel K; Carbonaro DA; Karlen AD; Khan S; Cornetta K; Rothe M; Schambach A; Kohn DB; Malech HL; McIvor RS; Puck JM; Cowan MJ
    Hum Gene Ther; 2017 Jan; 28(1):112-124. PubMed ID: 27611239
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Controlling genetic heterogeneity in gene-edited hematopoietic stem cells by single-cell expansion.
    Becker HJ; Ishida R; Wilkinson AC; Kimura T; Lee MSJ; Coban C; Ota Y; Tanaka Y; Roskamp M; Sano T; Tojo A; Kent DG; Yamazaki S
    Cell Stem Cell; 2023 Jul; 30(7):987-1000.e8. PubMed ID: 37385251
    [TBL] [Abstract][Full Text] [Related]  

  • 50. TRIAMF: A New Method for Delivery of Cas9 Ribonucleoprotein Complex to Human Hematopoietic Stem Cells.
    Yen J; Fiorino M; Liu Y; Paula S; Clarkson S; Quinn L; Tschantz WR; Klock H; Guo N; Russ C; Yu VWC; Mickanin C; Stevenson SC; Lee C; Yang Y
    Sci Rep; 2018 Nov; 8(1):16304. PubMed ID: 30389991
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gene therapy outpaces haplo for SCID-X1.
    Kohn DB
    Blood; 2015 Jun; 125(23):3521-2. PubMed ID: 26045591
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Stable and functional lymphoid reconstitution in artemis-deficient mice following lentiviral artemis gene transfer into hematopoietic stem cells.
    Benjelloun F; Garrigue A; Demerens-de Chappedelaine C; Soulas-Sprauel P; Malassis-Séris M; Stockholm D; Hauer J; Blondeau J; Rivière J; Lim A; Le Lorc'h M; Romana S; Brousse N; Pâques F; Galy A; Charneau P; Fischer A; de Villartay JP; Cavazzana-Calvo M
    Mol Ther; 2008 Aug; 16(8):1490-9. PubMed ID: 18560421
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gene knockout in highly purified mouse hematopoietic stem cells by CRISPR/Cas9 technology.
    Dong Y; Bai H; Dong F; Zhang XB; Ema H
    J Immunol Methods; 2021 Aug; 495():113070. PubMed ID: 33957108
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Transplantation of genetically modified cells in the treatment of children with SCID: great hopes and recent disappointments].
    Smogorzewska EM; Weinberg KI; Kohn DB
    Med Wieku Rozwoj; 2003; 7(1):27-34. PubMed ID: 13130167
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Site-Specific Gene Editing of Human Hematopoietic Stem Cells for X-Linked Hyper-IgM Syndrome.
    Kuo CY; Long JD; Campo-Fernandez B; de Oliveira S; Cooper AR; Romero Z; Hoban MD; Joglekar AV; Lill GR; Kaufman ML; Fitz-Gibbon S; Wang X; Hollis RP; Kohn DB
    Cell Rep; 2018 May; 23(9):2606-2616. PubMed ID: 29847792
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gene therapy improves immune function in preadolescents with X-linked severe combined immunodeficiency.
    Chinen J; Davis J; De Ravin SS; Hay BN; Hsu AP; Linton GF; Naumann N; Nomicos EY; Silvin C; Ulrick J; Whiting-Theobald NL; Malech HL; Puck JM
    Blood; 2007 Jul; 110(1):67-73. PubMed ID: 17369490
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gene editing of hematopoietic stem cells restores T-cell response in familial hemophagocytic lymphohistiocytosis.
    Dettmer-Monaco V; Weißert K; Ammann S; Monaco G; Lei L; Gräßel L; Rhiel M; Rositzka J; Kaufmann MM; Geiger K; Andrieux G; Lao J; Thoulass G; Schell C; Boerries M; Illert AL; Cornu TI; Ehl S; Aichele P; Cathomen T
    J Allergy Clin Immunol; 2024 Jan; 153(1):243-255.e14. PubMed ID: 37595758
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CRISPR-Cas9n-mediated ELANE promoter editing for gene therapy of severe congenital neutropenia.
    Nasri M; Ritter MU; Mir P; Dannenmann B; Kaufmann MM; Arreba-Tutusaus P; Xu Y; Borbaran-Bravo N; Klimiankou M; Lengerke C; Zeidler C; Cathomen T; Welte K; Skokowa J
    Mol Ther; 2024 Jun; 32(6):1628-1642. PubMed ID: 38556793
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BCL11A enhancer-edited hematopoietic stem cells persist in rhesus monkeys without toxicity.
    Demirci S; Zeng J; Wu Y; Uchida N; Shen AH; Pellin D; Gamer J; Yapundich M; Drysdale C; Bonanno J; Bonifacino AC; Krouse AE; Linde NS; Engels T; Donahue RE; Haro-Mora JJ; Leonard A; Nassehi T; Luk K; Porter SN; Lazzarotto CR; Tsai SQ; Weiss MJ; Pruett-Miller SM; Wolfe SA; Bauer DE; Tisdale JF
    J Clin Invest; 2020 Dec; 130(12):6677-6687. PubMed ID: 32897878
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gene Therapies for Primary Immune Deficiencies.
    Kohn LA; Kohn DB
    Front Immunol; 2021; 12():648951. PubMed ID: 33717203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.